Literature DB >> 2542356

Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.

D J Kwekkeboom1, F H de Jong, S W Lamberts.   

Abstract

We studied in vivo hormone levels and in vitro hormone and subunit release in a group of 22 patients who were operated upon because of a clinically nonfunctioning or gonadotroph pituitary adenoma. In vivo, 5 of the 22 patients, all men, had hypersecretion of FSH, LH beta, or alpha-subunit. An elevated ratio of serum alpha-subunit to LH and FSH was found in 6 of 8 women in vivo, although in all 6 women serum LH, FSH, and alpha-subunit levels were low. LH, FSH, alpha-subunit, LH beta, or a combination of these glycoprotein hormones could be demonstrated in 19 of 22 cultured adenomas. We conclude that 1) virtually all clinically nonfunctioning adenomas contain or release gonadotropins or their subunits in vitro; 2) in vivo hypersecretion of these hormones and subunits occurs infrequently, and in this series only in men; 3) an elevated ratio of alpha-subunit to LH and FSH is frequently found in women and may prove to be a useful diagnostic tool; 4) responses to TRH and bromocriptine do not depend on baseline gonadotropin levels, either in vitro or in vivo, implying that the distinction between gonadotroph adenomas and adenomas without hypersecretion of gonadotropins in vivo is absent where hormone dynamics are concerned.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542356     DOI: 10.1210/jcem-68-6-1128

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Receptor imaging in the diagnosis and treatment of pituitary tumors.

Authors:  D J Kwekkeboom; W W de Herder; E P Krenning
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  The silent corticotropinoma: is clinical diagnosis possible?

Authors:  B Ambrosi; P Colombo; D Bochicchio; M Bassetti; B Masini; G Faglia
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

Review 3.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

Review 4.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

5.  GH-, PRL-, POMC-, beta-TSH-, beta-LH-, beta-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data.

Authors:  A Münscher; M Schmid; W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.

Authors:  Y Reznik; F Chapon; N Lahlou; N Deboucher; J Mahoudeau
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

7.  In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas.

Authors:  K Saccomanno; P Gil del Alamo; M Bassetti; F Reza-Elahi; A Spada
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

8.  Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro.

Authors:  J M Alexander; A Klibanski
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Analysis of pituitary hormones and chromogranin A mRNAs in null cell adenomas, oncocytomas, and gonadotroph adenomas by in situ hybridization.

Authors:  R V Lloyd; L Jin; K Fields; W F Chandler; E Horvath; L Stefaneanu; K Kovacs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

10.  Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.

Authors:  S Borgato; L Persani; R Romoli; D Cortelazzi; A Spada; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.